AURORA, Colo., June 18, 2003 — GlobeImmune, Inc. today announced the closing of a Series A Preferred venture financing round. The round provides for up to a total of $8 million in two tranches, with closure of the second tranche dependent on achievement of certain milestones. Investors in the round include HealthCare Ventures LLC of Cambridge, MA, Morgenthaler Ventures of Menlo Park, CA and Sequel Venture Partners of Boulder, CO.
Dr. Timothy Rodell, Chief Executive Officer of GlobeImmune stated: “We are extremely pleased with the confidence in the Company and our team that this financing represents and with the quality of the investment group. The funding will enable us to accelerate the development of our vaccine projects and should allow us to identify additional products for clinical development in the coming months.”
The Company also announced the additions of Dr. Ralph Christoffersen of Morgenthaler Ventures, Augustine Lawlor of HealthCare Ventures and Dan Mitchell of Sequel Venture Partners to the board of directors where they join Dr. Rodell and Dr. Richard Duke, a Company founder.
GlobeImmune, Inc. is a private company developing products based on a novel, proprietary vaccine platform technology. The Company’s first product candidate, HIVAX-GS, a vaccine for HIV/AIDS, is expected to enter human clinical trials this year. The Company is also developing candidate vaccine products for other viral diseases and cancer. GlobeImmune is headquartered at the Fitzsimons BioScience Park in Aurora Colorado.
For additional information, please visit the company’s website at https://globeimmune.com/.